InflaRx N.V. (IFRX)
- GlobeNewswire
InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases
JENA, Germany, Sept. 03, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced the presentation of preclinical data for the company’s novel oral C5aR inhibitor, INF904, at the 2024 European Meeting on Complement in Human Diseases (EMCHD) being held in Lübeck, Germany, September 2 – 6, 2024. Members of InflaRx leadership also participated in a satellite symposium highlighting the
- GlobeNewswire
InflaRx Announces Participation in September Investor Events
JENA, Germany, Aug. 27, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will participate in two investor conferences in September 2024. Details are as follows: H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 9-11, 2024 in New York, NY InflaRx’s on-demand virtual presentation for the conference will be available beginning on September 9th. Infla
- Zacks
InflaRx N.V. (IFRX) Reports Q2 Loss, Lags Revenue Estimates
InflaRx (IFRX) delivered earnings and revenue surprises of -23.81% and 83%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
